Rybodyn is a biotechnology research company that develops therapeutics to train the immune system to detect and eradicate cancer internally.
Rybodyn has raised $10.0M in total funding. The most recent round was Seed. The last funding was announced in July 2026.
Rybodyn's investors include SOSV, SeaX Ventures, Massive Tech Ventures, U.S. Department of War, SOSV SF & NY (Fka IndieBio).
Rybodyn is headquartered in San Diego, United States.
Rybodyn is a biotechnology research company that develops therapeutics to train the immune system to detect and eradicate cancer internally.
Rybodyn is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rybodyn — Funding & Investors." VCBacked, July 23, 2026, https://www.vcbacked.co/company/rybodyn. Accessed August 13, 2026.
VCBacked. (2026). Rybodyn — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/rybodyn
{{cite web |title=Rybodyn — Funding & Investors |url=https://www.vcbacked.co/company/rybodyn |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated